Sanofi Drops Eczema Drug After Trial Setback | Business and Finance News

Sanofi’s big pivot: they’re scrapping amlitelimab, their once-promising eczema drug, after trials showed it didn’t outperform existing treatments — a major reversal just months after hype, following a leadership overhaul and a $1.1B acquisition. While it’s dead for atopic dermatitis, the drug’s still in play for celiac disease, with results due late 2026 — and Sanofi’s 2026 financial outlook remains intact. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/597499dd0192a069